Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis

Hepatology Research

Volumn 39, Issue 12, 2009, Pages 1178-1189

  Zhang, Xiaozhen ^a   Frank, Astrid C ^a   Gille, Christine M ^a   Daucher, Marybeth ^a   Kabat, Juraj ^a   Becker, Steven ^a   Lempicki, Richard A ^b   Cortez, Karoll J ^c   Polis, Michael A ^a   Subramanian, G Mani ^d   Kottilil, Shyam ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Hepatitis C virus cell culture system; Hepatocellular carcinoma; Tumor necrosis factor related apoptosis inducing ligand agonistic antibodies

Indexed keywords

ALPHA INTERFERON; CASPASE 3; CASPASE 7; DEATH RECEPTOR 4; DEATH RECEPTOR 5; INHIBITOR OF APOPTOSIS PROTEIN; LEXATUMUMAB; MAPATUMUMAB; RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BLOOD CELL; CARCINOMA CELL; CELL ISOLATION; CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MICROARRAY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION;

EID: 73849144386     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00568.x     Document Type: Article

References (37)

1. Schiff ER. Introduction: advances in antiviral therapy for chronic hepatitis c infection-the influence of genotype and HIV co-infection. Nat Clin Prac Gastroenterol Hepatol 2007; 4: S1-2.
2. Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-30.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
4. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
5. Yu ML, Huang CF, Dai CY, Huang JF, Chuang W.L. Longterm effects of interferon-based therapy for chronic hepatitis C. Oncology 2007; 72 (Suppl. 1): 16-23.
6. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
7. Sherman K.E. HCV and HIV: a tale of two viruses. Rev Gastroenterol Disord 2004; 4 (Suppl. 1): S48-54.
8. Coleman W.B. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3: 573-88.
9. Farazi PA, Depinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
10. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-48.
11. Igney FH, Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-88.
12. Okano H, Shiraki K, Inoue H et al. Over-expression of Smac promotes TRAIL-induced cell death in human hepatocellular carcinoma. Int J Mol Med 2003; 12: 25-8.
13. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006; 84: 87-98.
14. Humphreys RC, Halpern W. Trail receptors: targets for cancer therapy. Adv Exp Med Biol 2008; 615: 127-58.
15. Georgakis GV, Li Y, Humphreys R et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130: 501-10.
16. Greco FA, Bonomi P, Crawford J et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
17. Hotte SJ, Hirte HW, Chen EX et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-5.
18. Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92: 1430-41.
19. Srivastava R.K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-46.
20. Zhu H, Dong H., Eksioglu E. et al. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral Defense system. Gastroenterology 2007.
21. Herr I, Schemmer P, Buchler M.W. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007; 46: 266-74.
22. Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
23. Yen T.S. Nuclear factor kappaB and hepatitis C - is there a connection? Hepatology 2000; 31: 785-7.
24. Herbeuval JP, Boasso A, Grivel JC et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005; 105: 2458-64.
25. Herbeuval JP, Hardy AW, Boasso A et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005; 102: 13974-9.
26. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.
27. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
28. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel R.A. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007; 6: 66.
29. Kimberley FC, Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359-72.
30. Vucic D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr Cancer Drug Targets 2008; 8: 110-17.
31. Wu L, Wang Y, Tian D. Knockdown of survivin expression by siRNA induces apoptosis of hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 403-6.
32. Sakemi R, Yano H, Ogasawara S et al. X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. Oncol Rep 2007; 18: 65-70.
33. Fernandez-Luna J.L. Apoptosis regulators as targets for cancer therapy. Clin Transl Oncol 2007; 9: 555-62.
34. Plummer R, Attard G, Pacey S et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-94.
35. Gajewski T. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007; 25: 1305-7.
36. Marini P, Denzinger S, Schiller D et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006; 25: 5145-54.
37. Vulfovich M, Saba N. Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda. Curr Opin Mol Ther 2005; 7: 502-10.